Authors' Reply: Pharmacokinetic Issue May Influence the Perceived Cardiac Risk Posed by Ondansetron in Patients Undergoing Chronic Hemodialysis.
Sherine IsmailMichele Jonsson FunkJennifer E FlythePublished in: Journal of the American Society of Nephrology : JASN (2024)